Pluristyx, a Seattle, WA-based provider of tools, technologies and services for the development of cell therapies, raised a major fundraising.
The round was led by BroadOak Capital Partners with participation from existing investors and key opinion leaders across the life sciences industry.
The company intends to use the funds to expand its existing cGMP cell line and service portfolio and broaden partner access to its panCELLa platform.
Led by CEO Benjamin Fryer, Pluristyx, through its panCELLa platform, offers a portfolio of iPSC-based technologies, proprietary genetic engineering, and related tool-products and services to provide end-to-end client support throughout the products’ lifecycle. It is a provider of gene-edited iPSC and cell therapy solutions, accelerating customers’ path to clinic, and offering the route to commercialization for cell-based therapeutic products.
Commenting on the news, Benjamin Fryer said: “2023 was a remarkable year for us with the launch of our PluriBank pre-edited, clinical-grade, iPSC lines, and the signing of several major license and service agreements with industry leaders. In 2024 we are expanding our capacity and making more best-in-class tools for therapeutic development available to our customers. We appreciate the support of our investors and strategic advisors, and together we will accelerate the development of cell therapy technologies to deliver tomorrow’s cures, today.”
FinSMEs
21/12/2023